Increased centrosome number in BRCA-related breast cancer specimens determined by immunofluorescence analysis.

about

Increased centrosome number in BRCA-related breast cancer specimens determined by immunofluorescence analysis.

Item

http://www.wikidata.org/entity/Q51758191

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh-hant

name

Increased centrosome number in ...... y immunofluorescence analysis.

@en

Increased centrosome number in ...... y immunofluorescence analysis.

@nl

type

Item

label

Increased centrosome number in ...... y immunofluorescence analysis.

@en

Increased centrosome number in ...... y immunofluorescence analysis.

@nl

prefLabel

Increased centrosome number in ...... y immunofluorescence analysis.

@en

Increased centrosome number in ...... y immunofluorescence analysis.

@nl

P1476

Increased centrosome number in ...... by immunofluorescence analysis

@en

P2093

Akihiko Furuta

http://www.w3.org/2001/XMLSchema#string

Akihiko Suzuki

http://www.w3.org/2001/XMLSchema#string

Kaolu Sato

http://www.w3.org/2001/XMLSchema#string

Minoru Miyashita

http://www.w3.org/2001/XMLSchema#string

Natsuko Chiba

http://www.w3.org/2001/XMLSchema#string

Noriaki Ohuchi

http://www.w3.org/2001/XMLSchema#string

Tadashi Nomizu

http://www.w3.org/2001/XMLSchema#string

Takanori Ishida

http://www.w3.org/2001/XMLSchema#string

P2860

Comprehensive molecular portraits of human breast tumours

Regulation of the centrosome cycle

Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers.

Cancer statistics, 2015

Analysis of missense variation in human BRCA1 in the context of interspecific sequence variation

Hallmarks of 'BRCAness' in sporadic cancers

Predicting the likelihood of carrying a BRCA1 or BRCA2 mutation: validation of BOADICEA, BRCAPRO, IBIS, Myriad and the Manchester scoring system using data from UK genetics clinics.

Selecting a BRCA risk assessment model for use in a familial cancer clinic.

Phase I Study of Veliparib (ABT-888) Combined with Cisplatin and Vinorelbine in Advanced Triple-Negative Breast Cancer and/or BRCA Mutation-Associated Breast Cancer

Optimal selection of individuals for BRCA mutation testing: a comparison of available methods.

P304

2027-2035

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/CAS.13595

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

109

http://www.w3.org/2001/XMLSchema#string

P50

Gou Watanabe

Hiroshi Tada

P577

2018-05-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29601120

http://www.w3.org/2001/XMLSchema#string

P921

immunofluorescence microscopy

P932

5989840

http://www.w3.org/2001/XMLSchema#string